ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0221

A Multimodal Intervention Improves the Quantity and Quality of Disease Activity Measures Collection in a Multi-Centered National Rheumatoid Arthritis Network

Grant Cannon1, Beth Wallace2, Deana Lazaro3, Pascale Schwab4, Paul Monach5, Ankoor Shah6, Gail Kerr7, Andreas Reimold8, Joshua Baker9, Gary Kunkel10, Katherine Wysham11, Liron Caplan12, John Richards13, Aleksander Lenert14, Andrew Jones15, Ted Mikuls16, Maria I. ("Maio") Danila17, Bryant England16, Brian Sauer18, Jorge Rojas19 and Isaac Smith20, 1University of Utah and Salt Lake City VA, Salt Lake City, UT, 2Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 3VA New York Harbor Healthcare system, Short Hills, NJ, 4VA Portland and Oregon Health & Science University, Portland, OR, 5VA Boston Healthcare System, Boston, MA, 6Duke University, Durham, NC, 7Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 8Dallas VA Medical Center, Dallas, TX, 9University of Pennsylvania, Philadelphia, PA, 10University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 11VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 12Rocky Mountain Regional VAMC, Aurora, CO, 13Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 14University of Iowa, Iowa City, IA, 15VA Saint Louis and Washington University, Saint Louis, 16University of Nebraska Medical Center, Omaha, NE, 17University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, 18Salt Lake City VA/University of Utah, Salt Lake City, UT, 19VA Puget Sound Health Care System, Seattle, WA, 20Duke University Hospital, Durham, NC

Meeting: ACR Convergence 2025

Keywords: Disease Activity, Measurement Instrument, Quality Indicators, quality of care, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0210–0232) Measures & Measurement of Healthcare Quality Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Clinical guidelines recommend the use of disease activity measures (DAMs) in rheumatoid arthritis (RA) management. Measurement of DAMs is also a critical component of clinical and epidemiologic research in RA. The Veterans Affairs RA (VARA) registry is a prospective cohort study of Veterans with RA that is active at 16 VA Medical Centers. A VARA goal is to systematically collect and document eight DAM components for participants at each in-person clinic visit (Table1). A multimodal intervention was initiated to enhance DAMs collection. This report details preliminary results following three months of implementation of this planned 12-month program.

Methods: This intervention involved three phases: 1) baseline; 2) development: and 3) implementation (Table 1). Key activities included qualitative interviews with site investigators to confirm availability of electronic health record (EHR) tools for DAM collection, provision of additional EHR tools if needed, development of monthly just-in-time lists of VARA participant appointments, and monthly provider-specific feedback on DAMs collection performance and comparison to VARA registry overall performance. Verification and retrieval of documented DAM components in the EHR was accomplished through data extraction of note text form the VA Corporate Data Warehouse. Performance at each encounter, by provider and by VARA site over the 3-month implementation phase was compared to baseline performance using chi square testing.

Results: Between March 2024 through March 2025, 3,576 in-person rheumatology clinic visits occurred in 1,436 RA patients enrolled in VARA who were seen by 135 unique providers. The distribution of these visits and basic demographic information on these patients during the baseline, development, and implementation phases are listed (Table 1). Compared to baseline values, there was a significant increase in the documentation of individual DAM components, combined DAM components, and composite DAMs during the implementation phase with increases ranging from 5.8% to 10.4% (Table 2). Analyses limited to the 44 providers completing ≥5 clinical notes during both the baseline and implementation phases demonstrated an increase in the number of providers successfully documenting DAMs in >50% of encounters (Table 3). A separate analysis of DAMs collection by all providers at each VARA site also showed improvement in the number of VARA sites successfully documenting DAMs (Table 3).

Conclusion: This multimodal intervention increased DAM collection and documentation in clinical notes, expanded the number of providers consistently collecting DAMs, and enhanced the performance at VARA registry sites during an initial 3-month intervention phase. Ongoing monitoring will determine if additional performance improvement occurs through sustained intervention over a 12-month follow-up. This work demonstrates that collaborative actions in a multi-center registry can improve both the quantity and quality of high-yield clinical data collected to facilitate patient care and research. These methods may be applied in additional clinical settings to improve real-world collection of DAMs.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: G. Cannon: None; B. Wallace: None; D. Lazaro: None; P. Schwab: None; P. Monach: Boehringer-Ingelheim, 2; A. Shah: Adtium Bio, 2, Cabaletta Bio, 5, Horizon Therapeuatics, 5, Mitsubishi, 2; G. Kerr: Amgen, 2, Bristol-Myers Squibb(BMS), 2, CSL-Behring, 2, Janssen, 2, Novartis, 2, Pfizer, 2, Sanofi, 2, UCB, 2; A. Reimold: None; J. Baker: Amgen, 5; G. Kunkel: None; K. Wysham: None; L. Caplan: None; J. Richards: None; A. Lenert: None; A. Jones: None; T. Mikuls: Amgen, 2, 5, Merck/MSD, 1, Olatech Therapeutics, 1, UCB, 1; M. Danila: Boehringer-Ingelheim, 2, Pfizer, 5; B. England: Boehringer-Ingelheim, 2, 5; B. Sauer: None; J. Rojas: None; I. Smith: None.

To cite this abstract in AMA style:

Cannon G, Wallace B, Lazaro D, Schwab P, Monach P, Shah A, Kerr G, Reimold A, Baker J, Kunkel G, Wysham K, Caplan L, Richards J, Lenert A, Jones A, Mikuls T, Danila M, England B, Sauer B, Rojas J, Smith I. A Multimodal Intervention Improves the Quantity and Quality of Disease Activity Measures Collection in a Multi-Centered National Rheumatoid Arthritis Network [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/a-multimodal-intervention-improves-the-quantity-and-quality-of-disease-activity-measures-collection-in-a-multi-centered-national-rheumatoid-arthritis-network/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-multimodal-intervention-improves-the-quantity-and-quality-of-disease-activity-measures-collection-in-a-multi-centered-national-rheumatoid-arthritis-network/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology